Important TdaP/Autism Study Does Not Show Safety In Pregnancy; New Real-World Data Show Increase in Autism Per The Data They Ignored
Our timely critique of Becerra-Culqui et al. (2018) was declined for review by the publishing journal (Pediatrics). We have published it elsewhere.
Lyons-Weiler, J., Fujito, A., & Pajer, B. (2022). Maternal Gestational Tdap Vaccination and Autism: A Critique of Becerra-Culqui et al. (2018). International Journal of Vaccine Theory, Practice, and Research, 2(1), 287–300.
We report flaws and inconsistencies in a critically important study of autism risk following maternal Tdap vaccination. The authors of the 2018 study, Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder (BC18), concluded that Tdap gestational vaccination is not associated with increased autism risk and claimed to provide “evidence supporting the ACIP’s recommendation to vaccinate pregnant women”. Our observations, based on information from the study itself, challenge these conclusions. We find evidence of a peculiar study design and approach to data analysis forcing outcomes by arbitrary data adjustments, overlooked variables of importance such as Bordetella pertussis infection prevalence and vaccine injury rates, insufficient consideration of likely interactions between multiple historical medical challenges by vaccines and other interventions on their participants, exclusion from the study individuals likely at risk of vaccine intolerance due to genetics, and indications that the study samples were not representative of the general population. Their first-year data show a concerning spike in ASD rates, and their findings and conclusions did not hold up to real-world data, which currently reports 3.8% ASD rate in California. Our observations, based on information from the study itself, challenge the conclusions of Becerra-Culqui et al, 2018.
BioNTech 2022 SEC Filing: We May Not Be Able To Demonstrate Sufficient Efficacy or Safety of Our COVID-19 Vaccine. Significant Adverse Events Could Delay or Prevent Regulatory Approval
A notable change: ” Undesirable Side Effects” in 2021 Filing was upgraded to “Significant Adverse Events”
Just like in the 2021 Annual SEC Filing, Pfizer admits that due to safety concerns and the inability to demonstrate sufficient efficacy, they are not likely to receive regulatory approval.
A notable change: ” Undesirable Side Effects” in 2021 Filing was upgraded to “Significant Adverse Events”.
Will this damning documented admission be ignored again by the MSM and the majority of so-called Alternative media the same way they ignored BioNTech’s 2021 SEC Filing?
Get ready for the never-ending state of emergency that will allow criminal world governments to mandate experimental Gene Therapy poison under the Emergency Use Authorisation for years to com
You can download the entire document here: BioNTech SEC Filing